Worldwide, about 71 million people are infected with the hepatitis C virus (HCV) (Saracco et al., 2022). In the U.S., it is estimated that 57,500 people are affected by acute HCV annually, and about 2.4 million people have chronic HCV (CDC, 2020a; 2021a). The World Health Organization (WHO) have endorsed a global strategy to eradicate HCV by 2030 (Saracco et al., 2022). Over the past several years, new classes of medications have been developed that are both highly effective and tolerable, allowing substantially more patients to achieve a cure for this disease. Healthcare providers (HCPs) should have knowledge of treatment modalities for patients who have HCV.
The goal of this course is to provide nursing professionals, pharmaceutical professionals, and physicians in acute care with guidance on the disease course and management of patients with HCV, who are treatment-naïve without cirrhosis or who have compensated cirrhosis.